Early experiences with two new transcatheter mitral valve technologies were featured during the first two days of the EuroPCR conference in Paris, with some ups and downs.
Even though mitral valve disease is the most common type of heart valve condition in the U.S. and about 8 to 12 percent of the population will eventually develop significant...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?